Despite no strong evidence of clinical benefit, microdosing GLP-1s will likely continue as a strategy for some to profit off of the popular drug class.

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli ...

Eli Lilly is investing €2.6billion in a new Dutch factory, bringing around 500 jobs and a major boost to the Dutch biotech scene.

For ocular rosacea, dermatologists can do more than hand off patients to ophthalmology by asking the right questions and ...

Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised ...

Novo Nordisk's new CEO, Mike Doustdar, is under significant pressure as the company contends with declining stock prices, ...

Trump administration pressure on Big Pharma to focus investment on the US has raised concerns in Europe, and specifically the ...

US pharma group says region’s use of ‘one-way insurance system’ to keep down prices is not fair on the industry ...

Plus, inside the super secretive intelligence firm Black Cube and Pfizer takes no prisoners in its fight to buy Metsera ...

Lilly, an Indianapolis-based drugmaker, plans to build a $3 billion manufacturing plant in the Netherlands to boost ...